A case is reported of a 65-year-old male patient with schizophrenia who developed depersonalization–derealization syndrome following treatment with quetiapine, an atypical antipsychotic. The literature is reviewed for possible biological mechanisms that may account for this phenomenon.
Aghajanian G K, Sprouse J S, Rasmussen K (1987) Physiology of the midbrain serotonin systems. In H Y Meltzer (ed.), Psychopharmacolgy, the third generation of progress, pp. 141–149. Raven Press, New York
2.
British Medical Association.Royal Pharmaceutical Society of Great Britain (2001) British National Formulary41: 182-182
3.
Chopra H D, Beatson J A (1986) Psychotic symptoms in borderline personality disorder.Am J Psychiatry143: 1605–1607
4.
Comfort A (1982) Out of body experiences and migraine [letter]. Am J Psychiatry139: 1379–1380
5.
Fichtner C G, Olivier A, Quesney L F, Anderman F, Horowitz S (1992) Fluoxetine in depersonalisation disorder [letter]. Am J Psychiatry149: 1750–1751
6.
Gloor P, Olivier A, Quesney L F, Anderman F, Horowitz S (1982) The role of the limbic system in the experiential phenomena of temporal lobe epilepsy. Ann Neurol12: 129–144
7.
Goldstein J (1995) Preclinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs4: 291–298
8.
Goldstein J M (1996) Preclinical profile of ‘Seroquel’ (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In Holliday S G, Ancill R J, MacEwan G W (eds), Schizophrenia: breaking down the barriers. John Wiley & Sons Ltd, Chichester
9.
Hamilton M (1974) Fish's clinical psychopathology. Wright, Bristol
10.
Hollander E, Liebowitz M R, DeCaria C, Fairbanks J, Fallon B, Kleins D (1990) Treatment of depersonalisation with serotonin reuptake blockers. J Clin Psychopharm10: 200–203
11.
Hollander E, Carrasco J L, Mullen L S, Trungold S, DeCaria C M, Towey J (1992) Hemispheric dysfunction and depersonalisation. Biol Psychiatry31: 1157–1162
12.
Lehman H E, Cancro R (1985) Schizophrenia: clinical features. In Kaplan H I, Saddock B J (eds), Comprehensive textbook of psychiatry. Williams & Wilkins, Baltimore
13.
Liebowitz M R, Hollander E, Schneier F (1989) Fluoxetine treatment of obsessive–compulsive disorder: an open clinical trial. J Clin Psychopharmacol9: 423–427
14.
Maes M, Maes L, Suy E (1990) Symptom profiles of biological markers in depression: a multivariate study. Psychoneuroendocrinology15:29–37
15.
Nemiah J C (1989) Dissociative disorders. In Kaplan H I, Saddock B J (eds), Comprehensive textbook of psychiatry. Williams & Wilkins, Baltimore
16.
Nuller Y L (1982) Depersonalisation –symptoms, meaning, therapy. Acta Psychiatr Scand66: 451–458
17.
Putnam F W, Guroff J J, Silberman E K (1986) The clinical phenomenology of multiple personality disorder. Review of 100 cases. J Clin Psychiatry47: 285–293
18.
Sierra M, Berrios G E (1998) Depersonalisation: neurobiological perspectives. Biol Psychiatry44: 898–908
19.
Simeon D, Stein D J, Hollander E (1998) Treatment of depersonalisation disorder with clomipramine. Biol Psychiatry44:302–303
20.
Stein M B, Uhde T W (1989) Effects of caffeine and response to pharmacotherapy. Biol Psychiatry26:315–320
21.
Szymanski H V (1981) Prolonged depersonalisation after marijuana abuse. Am J Psychiatry138:231–233
22.
World Health Organization (1992) The ICD 10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organisation, Geneva
